Table 7.
Association of selected polymorphisms in HRR genes with late skin adverse events.
| LENT-SOMA | CTCAE v.3 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SNP | Genotype | 2/3, N (%) | OR (95% CI) | p | OR (95% CI)adj | p adj | 2, N (%) | OR (95% CI) | p | OR (95% CI)adj | p adj |
| NBN rs1805794 | CC | 15 (31.9) | Ref. | Ref. | 6 (12.8) | Ref. | Ref. | ||||
| CG | 14 (30.4) | 0.93 (0.39–2.25) | 0.878 | 1.14 (0.43–3.05) | 0.788 | 4 (8.7) | 0.65 (0.17–2.48) | 0.529 | 0.75 (0.18–3.13) | 0.695 | |
| GG | 4 (50.0) | 2.13 (0.47–9.71) | 0.327 | 2.93 (0.43–20.07) | 0.274 | 2 (25.0) | 2.28 (0.37–13.99) | 0.374 | 3.08 (0.31–30.81) | 0.339 | |
| CG + GG | 18 (33.3) | 1.07 (0.46–2.46) | 0.880 | 1.29 (0.50–3.31) | 0.594 | 6 (11.1) | 0.85 (0.26–2.85) | 0.798 | 0.98 (0.26–3.63) | 0.974 | |
| NBN rs709816 | AA | 12 (30.8) | Ref. | Ref. | 6 (15.4) | Ref. | Ref. | ||||
| AG | 17 (32.7) | 1.09 (0.45–2.67) | 0.846 | 1.22 (0.45–3.33) | 0.694 | 4 (7.7) | 0.46 (0.12–1.75) | 0.254 | 0.44 (0.11–1.85) | 0.262 | |
| GG | 4 (40.0) | 1.50 (0.36–6.31) | 0.580 | 2.52 (0.40–16.04) | 0.329 | 2 (20.0) | 1.38 (0.23–8.13) | 0.725 | 2.22 (0.22–21.91) | 0.496 | |
| AG + GG | 21 (33.9) | 1.15 (0.49–2.72) | 0.746 | 1.34 (0.51–3.53) | 0.555 | 6 (9.7) | 0.59 (0.18–1.98) | 0.392 | 0.59 (0.16–2.198) | 0.429 | |
| NBN rs1063054 | AA | 12 (28.6) | Ref. | Ref. | 3 (7.1) | Ref. | Ref. | ||||
| AC | 15 (31.9) | 1.17(0.47–2.91) | 0.732 | 1.497 (0.53–4.23) | 0.447 | 6 (12.8) | 1.90 (0.45–8.14) | 0.386 | 2.74 (0.54–13.85) | 0.222 | |
| CC | 6 (50.0) | 2.50 (0.67–9.31) | 0.172 | 3.19 (0.74–13.74) | 0.119 | 3 (25.0) | 4.33 (0.75–25.11) | 0.102 | 6.69 (0.90–49.51) | 0.063 | |
| AC + CC | 21 (35.6) | 1.38 (0.59–3.25) | 0.459 | 1.79 (0.67–4.76) | 0.245 | 9 (15.3) | 2.34 (0.59–9.23) | 0.225 | 3.42 (0.74–15.84) | 0.116 | |
| RAD51 rs1801320 | GG | 24 (32.9) | Ref. | Ref. | 10 (13.7) | Ref. | Ref. | ||||
| GC | 9 (32.1) | 0.97 (0.38–2.46) | 0.944 | 0.98 (0.35–2.78) | 0.975 | 2 (7.1) | 0.49 (0.10–2.37) | 0.371 | 0.46 (0.08–2.48) | 0.365 | |
| RAD51 rs1801321 | GG | 9 (26.5) | Ref. | Ref. | 2 (5.9) | Ref. | Ref. | ||||
| GT | 17 (31.5) | 1.28 (0.49–3.31) | 0.616 | 1.46 (0.51–4.18) | 0.481 | 7 (13.0) | 2.38 (0.47–12.22) | 0.298 | 2.76 (0.49–15.49) | 0.248 | |
| TT | 7 (53.8) | 3.24 (0.86–12.26) | 0.083 | 2.30 (0.50–10.57) | 0.286 | 3 (23.1) | 4.80 (0.70–32.90) | 0.110 | 3.18 (0.38–26.51) | 0.285 | |
| GT + TT | 24 (35.8) | 1.55 (0.62–3.86) | 0.345 | 1.599 (0.58–4.39) | 0.362 | 10 (14.9) | 2.81 (0.58–13.61) | 0.200 | 2.86 (0.54–15.12) | 0.216 | |
| RAD51 rs12593359 | TT | 10 (43.5) | Ref. | Ref. | 3 (13.0) | Ref. | Ref. | ||||
| GT | 17 (30.4) | 0.57 (0.21–1.54) | 0.267 | 0.85 (0.27–2.66) | 0.785 | 7 (12.5) | 0.95 (0.22–4.06) | 0.947 | 1.43 (0.28–7.23) | 0.665 | |
| GG | 6 (27.3) | 0.49 (0.14–1.70) | 0.260 | 0.52 (0.13–2.096) | 0.356 | 2 (9.1) | 0.67 (0.10–4.43) | 0.675 | 0.77 (0.10–5.98) | 0.799 | |
| GT + TT | 23 (29.5) | 0.54 (0.21–1.42) | 0.212 | 0.73 (0.25–2.14) | 0.571 | 9 (11.5) | 0.87 (0.22–3.52) | 0.845 | 1.20 (0.26–5.57) | 0.821 | |
| XRCC3 rs1799794 | AA | 12 (22.2) | Ref. | Ref. | 5 (9.3) | Ref. | Ref. | ||||
| AG | 16 (41.0) | 2.44 (0.99–6.02) | 0.054 | 1.82 (0.65–5.095) | 0.256 | 5 (12.8) | 1.44 (0.39–5.37) | 0.586 | 0.80 (0.19–3.43) | 0.765 | |
| GG | 5 (62.5) | 5.83 (1.22–28.00) | 0.028 | 10.90 (1.61–73.72) | 0.014 | 2 (25.0) | 3.27 (0.52–20.69) | 0.209 | 3.80 (0.44–32.68) | 0.224 | |
| AG + GG | 21 (44.7) | 2.83 (1.19–6.69) | 0.018 | 2.43 (0.92–6.39) | 0.073 | 7 (14.9) | 1.72 (0.51–5.82) | 0.387 | 1.07 (0.28–4.11) | 0.917 | |
| XRCC3 rs861539 | CC | 19 (43.2) | Ref. | Ref. | 6 (13.6) | Ref. | Ref. | ||||
| CT | 13 (28.9) | 0.54 (0.22–1.29) | 0.162 | 0.58 (0.21–1.56) | 0.278 | 5 (11.1) | 0.79 (0.22–2.81) | 0.718 | 0.83 (0.21–3.33) | 0.797 | |
| TT | 1 (8.3) | 0.12 (0.01–1.01) | 0.051 | 0.11 (0.01–1.10) | 0.060 | 1 (8.3) | 0.58 (0.06–5.31) | 0.626 | 0.72 (0.07–7.81) | 0.787 | |
| CT + TT | 14 (24.6) | 0.43 (0.18–1.00) | 0.050 | 0.45 (0.17–1.16) | 0.097 | 6 (10.5) | 0.75 (0.22–2.49) | 0.633 | 0.81 (0.22–3.02) | 0.755 | |
Adj: adjusted for arterial hypertension and treatment with taxanes. CI, confidence interval; CTCAE v.3., Common Terminology Criteria for Adverse Events, version 3.0; HRR, homologous recombination repair; LENT SOMA, Late Effects in Normal Tissues/Subjective, Objective, Management and Analytic; OR, odds ratio; SNP, single nucleotide polymorphism.